Drug-Induced Liver Injury: ACG and EASL Diagnosis with R-Ratio Hy’s Law RUCAM Causality and N-Acetylcysteine Management

Drug-Induced Liver Injury: ACG and EASL Diagnosis with R-Ratio Hy’s Law RUCAM Causality and N-Acetylcysteine Management

Author: gomdori, MDCategory: HepatologyReading time: 16 min

Executive Summary

Drug-induced liver injury (DILI) accounts for approximately 50% of acute liver failure in the United States, with acetaminophen overdose responsible for nearly half of cases and idiosyncratic reactions to prescription medications, herbal supplements, and dietary products responsible for the remainder. Diagnosis is one of exclusion: characterize the biochemical injury pattern using the R-ratio (ALT/ULN ÷ ALP/ULN) — hepatocellular if R ≥5, cholestatic if R ≤2, mixed if R 2–5 — then apply the RUCAM (Roussel Uclaf Causality Assessment Method) score to assess temporal relationship, exclusion of competing diagnoses, and dechallenge/rechallenge response. Hy’s Law (ALT >3× ULN with total bilirubin >2× ULN in the absence of cholestasis) identifies patients with a 10–50% mortality without transplantation and mandates immediate drug withdrawal and hepatology referral. The cornerstone of management is prompt withdrawal of the suspected agent, supportive care, and N-acetylcysteine (NAC) for acetaminophen-induced and selected non-acetaminophen idiosyncratic injury. Corticosteroids have a defined role in autoimmune-like DILI and immune checkpoint inhibitor hepatotoxicity. Liver transplant evaluation is indicated for King’s College criteria-positive acute liver failure and for progressive cholestatic DILI failing supportive measures.
~50%
Of US ALF cases
14/100k
Annual incidence
~10%
Hy’s Law mortality
>1,000
Drugs implicated (LiverTox)

S1. Pathophysiology and Drug Classes

Drug-induced liver injury arises through two fundamentally different mechanisms. Intrinsic (direct, dose-dependent) hepatotoxicity occurs predictably above a threshold dose in nearly all exposed individuals — the prototype is acetaminophen, where excess substrate overwhelms glutathione conjugation pathways and the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) covalently binds hepatocyte proteins, producing centrilobular necrosis within 24–72 hours. Idiosyncratic hepatotoxicity occurs unpredictably in 1 in 1,000 to 1 in 100,000 exposed individuals, generally without strict dose dependence, after a latency period of 5–90 days; mechanisms include reactive metabolite formation by polymorphic CYP enzymes, mitochondrial injury, immune-mediated drug-protein adduct presentation via specific HLA alleles, and adaptive immune failure. Immune-mediated idiosyncratic DILI may be hapten-driven (drug or metabolite covalently binds liver protein → MHC class I/II presentation → CD4/CD8 T-cell hepatitis) or may resemble systemic hypersensitivity (DRESS) with rash, eosinophilia, fever, and lymphadenopathy.

Most common implicated agents

ClassExamplesTypical patternNotable features
Analgesic — intrinsicAcetaminophen (paracetamol)Hepatocellular (ALT often >1000–10,000 U/L)Most common cause of US ALF; treat with NAC
AntibioticsAmoxicillin-clavulanate (most common idiosyncratic in West), isoniazid, nitrofurantoin, minocycline, fluoroquinolones, macrolides, sulfa drugsCholestatic (amox-clav, macrolides) or hepatocellular (INH, nitrofurantoin)Amox-clav latency 1–8 weeks; INH 2–6 months
AntiepilepticsPhenytoin, carbamazepine, valproate, lamotrigine, phenobarbitalHepatocellular ± hypersensitivity (DRESS)HLA-B*15:02 with carbamazepine in Asians; valproate mitochondrial toxicity in children <2 y
StatinsAll HMG-CoA reductase inhibitorsHepatocellular (mostly mild ALT elevation)Severe DILI rare (<1/100,000); routine LFT monitoring not recommended
AntifungalsKetoconazole, itraconazole, terbinafine, fluconazoleHepatocellular or mixedKetoconazole highest risk; check baseline + monthly LFTs for terbinafine
AntituberculousIsoniazid, rifampin, pyrazinamideHepatocellular (synergistic with INH + RIF)Risk increases with age >35, HBV/HCV, alcohol; baseline + monthly LFTs
Immune checkpoint inhibitorsPembrolizumab, nivolumab, ipilimumab, atezolizumab, durvalumabHepatocellular ± cholestatic ± immune-mediated3–9% incidence; highest with combo (CTLA-4 + PD-1); steroid-responsive
NSAIDsDiclofenac, ibuprofen, sulindac, nimesulideHepatocellular or autoimmune-likeDiclofenac risk highest; check 2–6 month latency
Antineoplastic — chemoMethotrexate, busulfan, cyclophosphamide, oxaliplatin (sinusoidal obstruction)Variable — fibrosis (MTX), VOD/SOS, steatohepatitis (oxaliplatin)Methotrexate cumulative-dose threshold; FibroScan monitoring
AnestheticHalothane (rare now), isoflurane, sevofluraneHepatocellular — repeat exposure increases riskHalothane hepatitis once classic; halt all halogenated anesthetics
Herbal & dietary supplementsGreen tea extract (EGCG), kava, Garcinia cambogia, anabolic steroids, Ma huang, comfrey, He shou wu, HydroxycutVariable — anabolic androgens cause cholestasis; green tea hepatocellular~20% of US DILIN registry; underreported; review ALL OTC products
Antiplatelet/anticoagulantTiclopidine, clopidogrel, warfarin (rare), DOACs (very rare)Cholestatic (ticlopidine) or hepatocellularTiclopidine latency 1–3 months
CardiovascularAmiodarone (steatohepatitis), methyldopa, hydralazineSteatohepatitis (amiodarone — months to years); autoimmune-like (methyldopa, hydralazine)Amiodarone cumulative dose >100 g; baseline + 6-month LFTs; phospholipidosis
DILI — Hepatocellular to Mixed to Cholestatic Patterns NAFLD liver fibrosis progression from normal liver to HCC through fibrosis stages F0-F4 DILI — Hepatocellular to Mixed to Cholestatic Patterns Progression rate: ~1% per year F0→F4 in NASH Normal Liver No fat → Steatosis F0 Fat >5% → NASH F1 Perisinusoidal fibrosis → F2 Periportal fibrosis → F3 Bridging fibrosis → Cirrhosis F4 Nodular, portal HTN → HCC Hepatocellular Carcinoma F0–F2: Potentially reversible with weight loss/treatment | F3–F4: Partial regression possible | HCC: Irreversible
Drug-Induced Liver Injury — Histology Progression

S2. Clinical Presentation, R-Ratio, and Hy’s Law

The clinical phenotype of DILI is highly variable, ranging from asymptomatic enzyme elevation discovered on routine labs (most common) to fulminant acute liver failure. Symptoms — when present — include fatigue, anorexia, nausea, right upper quadrant discomfort, pruritus (cholestatic), jaundice, dark urine, and clay-colored stools. Hypersensitivity features (rash, eosinophilia, fever) are uncommon but specific when present. Latency between drug exposure and biochemical abnormality is one of the most useful clues: most idiosyncratic DILI presents within 5 days to 12 weeks of starting a new medication, although some agents (nitrofurantoin, amiodarone, methotrexate) have latencies of months to years.

R-ratio: pattern of injury

The R-ratio classifies DILI into hepatocellular, cholestatic, or mixed pattern based on the relative elevations of ALT and alkaline phosphatase at presentation. Calculate as: R = (ALT / ULN of ALT) ÷ (ALP / ULN of ALP). The pattern dictates differential diagnosis priorities and informs prognosis and treatment.

R-RatioPatternTypical offendersDifferential to exclude
R ≥ 5HepatocellularAcetaminophen, INH, NSAIDs, methotrexate, statins, halothane, ICIsViral hepatitis (A, B, C, E, EBV, CMV, HSV), AIH, ischemic, Wilson, Budd-Chiari
R 2–5MixedAmox-clav (early), trimethoprim-sulfa, phenytoin, carbamazepineAIH, biliary obstruction, sepsis, infiltrative
R ≤ 2CholestaticAmox-clav (late), erythromycin, anabolic steroids, oral contraceptives, ticlopidineBiliary obstruction (US/MRCP), PBC, PSC, infiltrative (granulomatous)

Hy’s Law — the 10% mortality marker

Hy’s Law (FDA criteria for severe DILI): ALT >3× ULN AND total bilirubin >2× ULN in the absence of significant cholestasis (ALP <2× ULN) and in the absence of an alternative explanation. Mortality or transplantation rate of 10–50% — mandates immediate drug withdrawal, hospitalization, and hepatology consultation.

Hy’s Law was derived by Hyman Zimmerman from observations that hepatocellular jaundice from a drug carries far worse prognosis than enzyme elevation alone. The bilirubin requirement reflects the failing synthetic and excretory capacity of an injured liver — once jaundice appears, the threshold for transplant evaluation is low. Always recalculate Hy’s Law when LFTs progress: a patient who initially had isolated transaminitis but later develops bilirubin >2× ULN has crossed into Hy’s Law territory and is at high risk.

R-ratio classification chart Hepatocellular cholestatic mixed pattern thresholds R=2 R=5 HEPATOCELLULAR R ≥ 5 APAP, INH, ICIs, NSAIDs MIXED R = 2–5 CHOLESTATIC R ≤ 2 — amox-clav, OCP R = (ALT/ULN) ÷ (ALP/ULN)
Figure 1. R-ratio bands defining hepatocellular, mixed, and cholestatic DILI patterns.
Drug-Induced Liver Injury — Comparison Comparison table: Drug-Induced Liver Injury — Comparison Hepatocellular Cholestatic Mixed Hy’s Law Description R ≥5 (ALT >3×ULN); APAP, methotrexate, immune checkpoint, antiepileptic R ≤2 (ALP >2×ULN); macrolides, anabolic steroids, oral contraceptives R 2-5; phenytoin, sulfonamides Hepatocellular DILI + bilirubin >2×ULN — 10% mortality without transplant
Drug-Induced Liver Injury — Comparison

S3. Diagnostic Workup and RUCAM Causality Score

DILI remains a diagnosis of exclusion — there is no confirmatory test. The workup must rule out viral, autoimmune, vascular, biliary, and metabolic causes before attributing injury to a drug. ACG (2021) and EASL (2019) recommend the following baseline panel in any patient with suspected DILI.

Required exclusion workup

CategoryTestsTrigger
Viral hepatitisHAV IgM, HBsAg + anti-HBc IgM, anti-HCV + HCV RNA, HEV IgM/IgG (especially >50 years or immunocompromised), EBV/CMV PCR if atypical lymphocytes or feverAll patients with new ALT/AST elevation
Autoimmune hepatitisANA, ASMA, anti-LKM-1, IgG, AMA (for PBC); consider liver biopsy if AIH suspectedFemale, hepatocellular pattern, no clear drug temporality
Biliary obstructionRUQ ultrasound — assess CBD diameter, gallstones, masses; MRCP if US non-diagnostic and cholestaticCholestatic or mixed pattern, jaundice
MetabolicFerritin + transferrin saturation (hemochromatosis), ceruloplasmin + 24h urine copper (Wilson if <40 y), alpha-1 antitrypsinYoung patient or chronic enzyme elevation without obvious cause
VascularDoppler ultrasound (Budd-Chiari, portal vein thrombosis); MRI/CT venography if abnormalAcute hepatocellular pattern with hepatomegaly, ascites, or thrombophilia
Toxic/ingestionAcetaminophen level (immediately, even if denied); urine drug screen, alcohol level, herbal/supplement historyEvery patient; especially altered mental status or unintentional overdose
Liver biopsyIndicated when diagnosis unclear, AIH suspected, severe ongoing injury despite drug withdrawal, or cholestatic pattern persists >3 monthsSelected cases — confirms necroinflammation, eosinophilic infiltrate, granulomas, or AIH features

RUCAM causality score (Roussel Uclaf 2016 update)

The RUCAM score systematically grades the likelihood that a specific drug caused the observed liver injury, with separate algorithms for hepatocellular and cholestatic/mixed patterns. Score components include:

  • Time to onset (5–90 days suggestive, >90 days possible) — score +1 to +2
  • Course after drug discontinuation (dechallenge) — >50% drop in ALT within 8 days highly suggestive (+3); <50% drop within 30 days possible (+2); no change or worsening unfavorable
  • Risk factors — age >55, alcohol use, pregnancy
  • Concomitant medications — exclude known hepatotoxins or score against if competitor exists
  • Exclusion of competing causes (viral, biliary, metabolic) — full exclusion +2
  • Previous information on the drug (LiverTox database, label warnings) — known hepatotoxin +2
  • Rechallenge — positive rechallenge = +3 (rarely available; ethically discouraged unless inadvertent)
RUCAM totalCausality
≤ 0Excluded
1–2Unlikely
3–5Possible
6–8Probable
≥ 9Highly probable
LiverTox resource: The NIH LiverTox database (livertox.nih.gov) catalogues hepatotoxicity profiles of more than 1,200 drugs and supplements, with onset patterns, severity grading (A–E likelihood), and case reports. Reference it before assigning causality — a drug with extensive prior reports of cholestatic injury starting at week 4 carries far stronger causality than a drug with no published cases.

S4. Management — Drug Withdrawal, NAC, Corticosteroids, Transplant

Step 1 — Immediate drug withdrawal

The single most important intervention in suspected DILI is prompt withdrawal of the offending agent. Stop the suspected drug and any non-essential potentially hepatotoxic concomitant medications. For Hy’s Law-positive patients, hospitalize and place a hepatology consult immediately. The expected pattern after dechallenge is gradual normalization of LFTs over 4–12 weeks for hepatocellular DILI and 2–6 months for cholestatic DILI; failure to improve within this window suggests an alternative diagnosis or progression to chronic DILI/vanishing bile duct syndrome.

Step 2 — Supportive care

  • Avoid all non-essential medications and herbal supplements
  • Adequate hydration; correct any volume depletion
  • Treat coagulopathy with vitamin K (Vitamin K 10 mg SC daily × 3 days) only if response confirms vitamin K deficiency rather than hepatic synthetic failure; FFP if active bleeding
  • Treat hepatic encephalopathy with Lactulose 30 mL PO q6h titrated to 2–3 soft stools/day ± Rifaximin 550 mg PO BID
  • Treat pruritus in cholestatic DILI: Cholestyramine 4 g PO BID–QID, Ursodeoxycholic acid 13–15 mg/kg/day PO divided BID, or Rifampin 150–300 mg PO daily

Step 3 — N-acetylcysteine (NAC)

NAC is the antidote for acetaminophen-induced hepatotoxicity and has been shown to improve transplant-free survival in non-acetaminophen acute liver failure with early-stage encephalopathy (ALFSG study, NEJM 2009). NAC replenishes hepatic glutathione, scavenges free radicals, improves microcirculatory oxygen delivery, and modulates inflammatory cytokines.

IndicationIV protocol (preferred)Oral protocol
Acetaminophen overdose (any pattern)NAC 150 mg/kg IV in 200 mL D5W over 60 min → 50 mg/kg over 4 h → 100 mg/kg over 16 h (21-h Prescott protocol; total 300 mg/kg)NAC 140 mg/kg PO loading → 70 mg/kg PO q4h × 17 doses (72 h total)
Non-acetaminophen ALF with grade I–II encephalopathySame Prescott IV protocol — continue 21 h or longer until improvementNot validated
Non-acetaminophen DILI without ALFRoutine NAC not recommended—
Acetaminophen overdose timing: Use the Rumack-Matthew nomogram (4-hour level >150 μg/mL = treat) for single-dose ingestion within 24 hours. For unknown or staggered ingestions, treat empirically with NAC if any concern. NAC is most effective within 8 hours of ingestion but provides benefit even at 24+ hours and during ALF.

Step 4 — Corticosteroids in selected DILI

IndicationRegimenNotes
Drug-induced autoimmune hepatitis (DI-AIH; minocycline, nitrofurantoin, methyldopa)Prednisone 30–40 mg PO daily taper over 4–8 weeks based on LFT responseLiver biopsy should confirm AIH features; consider azathioprine if steroid-dependent
DRESS syndrome with hepatic involvementPrednisone 1 mg/kg/day PO with slow taper over 3–6 monthsMonitor for HHV-6 reactivation; refer to dermatology + hepatology
ICI-induced hepatitis grade 2 (ALT 3–5× ULN)Hold ICI; Methylprednisolone 0.5–1 mg/kg/day IV → Prednisone 1 mg/kg/day PO taper over 4 weeksResume ICI when grade ≤1; use ASCO/SITC algorithm
ICI-induced hepatitis grade 3–4 (ALT >5× ULN or bilirubin >3× ULN)Permanently discontinue ICI; Methylprednisolone 1–2 mg/kg/day IV; if no improvement in 3–5 days add Mycophenolate mofetil 500–1000 mg PO BIDAvoid infliximab (hepatotoxic); consider tacrolimus for refractory cases
Idiopathic idiosyncratic DILI without AIH featuresNO routine steroidsNot supported by trial data; risk of infection outweighs benefit

Step 5 — Liver transplant evaluation

King’s College Criteria for ALF transplant — acetaminophen: Arterial pH <7.30 OR (INR >6.5 AND creatinine >3.4 mg/dL AND grade III/IV encephalopathy). Non-acetaminophen ALF: INR >6.5 alone OR any 3 of: age <10 or >40, etiology non-A/non-B hepatitis or drug, jaundice-to-encephalopathy >7 days, INR >3.5, bilirubin >17.5 mg/dL. Refer to transplant center within hours of meeting criteria.
When to refer urgently: Any patient meeting Hy’s Law (ALT >3× + bili >2× ULN) — same-day hepatology consult. Encephalopathy of any grade — transfer to liver transplant center. INR >1.5 with progressive transaminitis — admit. ICI-induced grade 3+ hepatitis — multidisciplinary oncology + hepatology. Pregnant patient with severe DILI — maternal-fetal medicine + transplant center.

S5. Special Scenarios

Acetaminophen toxicity

Acetaminophen is the leading cause of acute liver failure in the US (~46% of ALF cases). Single-dose ingestion ≥7.5 g (or ≥150 mg/kg in children) produces significant hepatotoxicity in most adults; chronic supratherapeutic dosing (≥4 g/day with malnutrition or alcohol) can cause injury at much lower doses. Plot the 4-hour serum level on the Rumack-Matthew nomogram (treatment line: 150 μg/mL at 4 h, 75 μg/mL at 8 h, 37.5 μg/mL at 12 h). For staggered ingestions, unknown timing, or chronic toxicity, do not rely on the nomogram — treat empirically with full NAC course if ALT is elevated or any concern exists. The peak ALT typically occurs at 48–96 hours; a falling ALT with rising INR and bilirubin is the early warning of evolving ALF.

Herbal and dietary supplements (HDS)

HDS account for approximately 20% of cases in the US Drug-Induced Liver Injury Network (DILIN) registry — a fivefold increase over the past 15 years. The most common implicated agents are anabolic androgenic steroids (cholestatic, often prolonged), green tea extract (high-dose EGCG, hepatocellular), Garcinia cambogia (mixed), Hydroxycut formulations, kava (banned in EU), Ma huang (ephedra), He shou wu, comfrey (pyrrolizidine alkaloid VOD/SOS), and various multi-ingredient bodybuilding products. Always ask explicitly about ALL supplements, teas, weight-loss products, and bodybuilding aids — patients commonly do not consider these “drugs” and will not volunteer the history.

Immune checkpoint inhibitor (ICI) hepatitis

ICI hepatitis occurs in 3–9% of patients receiving anti-PD-1/PD-L1 monotherapy and 13–25% with combination CTLA-4 + PD-1 therapy (typically nivolumab + ipilimumab). Onset is usually 6–14 weeks after the first dose but can occur as early as 1 week or as late as 1 year. The injury pattern is most often hepatocellular but can be cholestatic or mixed. Liver biopsy shows lobular hepatitis with sinusoidal lymphocytic infiltrate (predominantly CD8+ T cells), endothelialitis, and granulomas — distinguishable from AIH (which has plasma cell-rich portal infiltrate and interface hepatitis). Management follows ASCO/SITC grading: grade 1 (ALT ≤3× ULN) — continue ICI with weekly monitoring; grade 2 — hold ICI + corticosteroids; grade 3–4 — permanent discontinuation + high-dose steroids ± MMF or tacrolimus for steroid-refractory cases.

Pregnancy

DILI in pregnancy is uncommon but the differential includes acute fatty liver of pregnancy (AFLP), HELLP syndrome, intrahepatic cholestasis of pregnancy (ICP), and viral hepatitis E (high mortality). Workup must include LFTs, CBC, coagulation, fibrinogen, glucose (AFLP causes hypoglycemia), bile acids (ICP >10 μmol/L), HEV IgM, and obstetric ultrasound. NAC is safe in pregnancy. Most other DILI treatments are reasonable except for valproate (replacement only when essential) and certain hepatotoxic chemotherapy.

Re-exposure rules

Once a probable or highly probable DILI has been attributed to a specific drug, lifelong avoidance is recommended in nearly all cases. Cross-reactivity within drug classes (e.g., other beta-lactams after amox-clav DILI) is incompletely defined; consider class avoidance only for severe DILI, anaphylactic features, or DRESS. For essential medications (e.g., antiepileptics, antitubercular drugs), structured reintroduction with close LFT monitoring under specialist supervision may be considered, but inadvertent rechallenge has caused fatal hepatic necrosis and is generally contraindicated.

Practice Insights: DILI — R-Ratio Pattern Recognition, Hy’s Law Severity Flag, and Empirical NAC for Non-APAP

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Transaminases that begin to fall in drug-induced liver injury can mean recovery or a failing liver, and only the pattern and the bilirubin separate the two: (1) R-ratio (ALT/ULN ÷ ALP/ULN) calculated at presentation classifies the injury pattern and guides differential diagnosis; (2) Hy’s Law (ALT > 3× ULN + bilirubin > 2× ULN + no other cause) flags severe DILI requiring close monitoring and transplant readiness; (3) IV NAC has been extended from acetaminophen overdose to severe non-APAP DILI per Mendizabal 2009 evidence. The “stop the drug and watch” approach has been refined by structured causality assessment and biomarker-guided escalation.

R-ratio classifies injury pattern + narrows differential

R-ratio = (ALT/ULN) ÷ (ALP/ULN) calculated at presentation. R > 5: hepatocellular pattern (acetaminophen, anti-TB drugs, NSAIDs, statins, antiepileptics, immune checkpoint inhibitors). R < 2: cholestatic pattern (amoxicillin-clavulanate most common, anabolic steroids, chlorpromazine, sulfonamides). R 2-5: mixed (carbamazepine, phenytoin, sulfasalazine). Pattern recognition narrows the differential dramatically — for cholestatic DILI experienced clinicians think amox-clav first, for hepatocellular they think acetaminophen + isoniazid first. Pattern can also evolve over course of injury — initial hepatocellular may transition to mixed or cholestatic with resolution.

Hy’s Law flags severe DILI with ~10% mortality risk

Hy’s Law: ALT > 3× ULN PLUS bilirubin > 2× ULN in the absence of alternative cause = severe DILI with approximately 10% mortality or transplant risk. This is a clinical pearl from Hyman Zimmerman that has held up across decades of pharmacovigilance. When Hy’s Law is positive, seasoned clinicians admit for monitoring, daily LFTs and INR, hepatology consultation, and consider early transfer to transplant center if INR rising or encephalopathy develops. ALT level alone (even > 1000) without bilirubin elevation has better prognosis. The combination is the mortality predictor.

RUCAM causality scoring + LiverTox database

RUCAM (Roussel Uclaf Causality Assessment Method) provides standardized causality assessment: 7 components scored (time to onset, course after withdrawal, risk factors, concomitant drugs, exclusion of non-drug causes, prior literature, response to rechallenge). Total score: ≥ 9 highly probable, 6-8 probable, 3-5 possible, 1-2 unlikely, ≤ 0 excluded. Experienced practitioners use RUCAM in any case with ≥ 2 suspect drugs or ambiguous clinical picture. The NIH LiverTox database (livertox.nih.gov) provides drug-specific likelihood scores (A-E) and characteristic patterns — invaluable reference for any DILI workup.

IV NAC for severe DILI — extended beyond acetaminophen

The Mendizabal 2009 trial demonstrated IV N-acetylcysteine improved transplant-free survival in non-acetaminophen acute liver failure with early-stage encephalopathy. Experienced clinicians extend NAC empirically to severe non-APAP DILI with progressive hepatic dysfunction (rising INR, encephalopathy, ALT trending up despite drug discontinuation): 150 mg/kg over 1 hour loading, then 50 mg/kg over 4 hours × 4 doses, then 100 mg/kg over 16 hours continuous. Cost and toxicity minimal; potential mortality benefit substantial. For pure acetaminophen DILI, NAC protocol is the same. Corticosteroids ONLY for immune-mediated DILI patterns (immune checkpoint inhibitor hepatitis, autoimmune-like DILI confirmed by biopsy) — not routine.

Anonymized Case: Amoxicillin-Clavulanate Cholestatic DILI with Hy’s Law

A man in his late fifties presented 4 weeks after completing a 10-day course of amoxicillin-clavulanate (875/125 mg BID for sinusitis) with progressive jaundice, pruritus, fatigue, and dark urine. No abdominal pain. No fever. Vital signs stable. Exam: scleral icterus, no hepatosplenomegaly, no peripheral edema, no asterixis. Labs: total bilirubin 8.5 mg/dL (predominantly direct), ALT 220 U/L (5.5× ULN), AST 180 U/L, ALP 480 U/L (4.0× ULN), GGT 580, albumin 3.8, INR 1.1, CBC normal. R-ratio: (220/40) / (480/120) = 5.5 / 4.0 = 1.4 — cholestatic pattern. Workup for alternative causes: HAV IgM negative, HBV surface antigen and core antibody negative, HCV antibody negative, HEV antibody negative, abdominal ultrasound with no biliary dilation or mass, autoimmune workup (ANA, ASMA, AMA) negative, IgG normal. Hy’s Law POSITIVE: ALT > 3× ULN + bilirubin > 2× ULN with no alternative cause. RUCAM score 8 (probable): typical time to onset 4 weeks after a known hepatotoxic drug, no concomitant drugs, no risk factors, exclusions negative, well-documented hepatotoxicity for amox-clav, +2 for resolution after withdrawal. LiverTox database confirmed amox-clav as one of the most common causes of cholestatic DILI (likelihood score A). Diagnosis: amox-clav cholestatic DILI. Treatment: supportive (no further amox-clav exposure, careful drug review for any other hepatotoxic exposures); given Hy’s Law positive, monitored as inpatient with daily LFTs and INR. Course: bilirubin peaked at 12.5 at week 2, ALT peaked at 280 at week 1, then both declined. INR remained stable at 1.0-1.2. No encephalopathy developed. Discharged hospital day 7. Resolution complete by week 8. Lifetime avoidance of amox-clav documented in chart.

The takeaway: R-ratio 1.4 (cholestatic) + Hy’s Law positive + RUCAM 8 (probable) + LiverTox database high-likelihood for amox-clav → diagnostic confidence and supportive management. Hy’s Law flagged the case for inpatient monitoring rather than outpatient observation. Resolution after withdrawal completed the RUCAM causality assessment. The “stop and watch” approach worked because R-ratio + LiverTox confirmed amox-clav as etiology without need for biopsy.

Four Protocol Deviations Seasoned Clinicians Now Default To

  1. R-ratio (ALT/ULN ÷ ALP/ULN) calculated at presentation classifies pattern. R > 5 hepatocellular (APAP, INH, NSAIDs, statins, antiepileptics, ICI); R < 2 cholestatic (amox-clav most common, anabolic steroids, chlorpromazine); R 2-5 mixed. Pattern narrows differential.
  2. Hy’s Law (ALT > 3× ULN + bilirubin > 2× ULN + no alternative cause) triggers inpatient monitoring. ~10% mortality/transplant risk per Hyman Zimmerman observation. Daily LFTs + INR + early hepatology consult; transfer to transplant center if INR rising or encephalopathy.
  3. RUCAM standardized causality assessment + LiverTox database for drug-specific likelihood. RUCAM ≥ 9 highly probable, 6-8 probable, 3-5 possible. LiverTox (livertox.nih.gov) provides A-E likelihood for > 1000 drugs. Use RUCAM for cases with multiple suspects or ambiguous picture.
  4. IV NAC for severe non-APAP DILI per Mendizabal 2009 — empirical for progressive hepatic dysfunction. 150 mg/kg over 1 hr load → 50 mg/kg over 4 hr × 4 → 100 mg/kg over 16 hr continuous. Corticosteroids ONLY for immune-mediated DILI (ICI hepatitis, autoimmune-like) — not routine.
DILI bedside protocol: R-ratio pattern + Hy’s Law severity + RUCAM causality + NAC management Two-panel diagram showing DILI assessment with R-ratio pattern recognition + Hy’s Law severity flag and RUCAM causality + management ladder. DILI: R-Ratio + Hy’s Law + RUCAM + NAC Management Panel A: Pattern + Severity Flag R-ratio = (ALT/ULN) ÷ (ALP/ULN) R > 5: HEPATOCELLULAR APAP, INH, NSAIDs, statins, AED, ICI R < 2: CHOLESTATIC Amox-clav (most common), anabolic steroids, chlorpromazine, sulfonamides R 2-5: MIXED Carbamazepine, phenytoin, sulfasalazine Pattern may evolve over course Hy’s Law (severe DILI flag): ALT > 3× ULN + bilirubin > 2× ULN + no alternative cause → ~10% mortality/transplant risk Inpatient monitoring + early hepatology Panel B: RUCAM + Management RUCAM causality (7 components): ≥ 9 highly probable 6-8 probable 3-5 possible; ≤ 2 unlikely LiverTox database (livertox.nih.gov): A-E likelihood for > 1000 drugs Patterns + characteristic features Treatment (severe DILI): STOP offending agent (most critical) IV NAC 150/50/100 mg/kg protocol (Mendizabal 2009) Corticosteroids ONLY for: ICI hepatitis (checkpoint inhibitor) Autoimmune-like DILI (biopsy confirmed) Hy’s Law positive + Hy progressing → transfer to transplant center; King’s College Criteria for ALF • Workup alternatives: HAV/B/C/E IgM, autoimmune (ANA, ASMA, AMA), imaging (US, MRCP), Wilson if young • Document lifetime avoidance of offending drug; alternate-drug selection for the original indication
RELATED TOOL
Pharmacogenomic Pre-Prescribing Check — before writing clopidogrel, allopurinol, abacavir, carbamazepine, a thiopurine or warfarin — does genotype change anything, and is testing worthwhile?

S6. Pearls, Pitfalls, and FAQ

Pearl — Hy’s Law triggers immediate actionOnce ALT >3× ULN AND total bilirubin >2× ULN, mortality without transplantation reaches 10–50%. Do not wait for further deterioration — stop the drug, hospitalize, consult hepatology, and check INR and lactate. Many fatal DILI cases were preventable if the Hy’s Law signal had triggered prompt withdrawal rather than continued treatment for an additional dose or two.
Pitfall — Forgetting to check acetaminophen levelAlways check an acetaminophen level on initial presentation of any acute liver injury, even when the patient denies acetaminophen use, denies overdose, or has a mechanism (e.g., antibiotic ingestion) that should explain the picture. Co-ingestion or unwitting toxicity from combination products is common; the level adds nothing if negative and changes management entirely if positive.
Pearl — Ask about ALL supplements explicitlyPatients regularly fail to disclose herbal teas, bodybuilding powders, weight-loss products, and naturopathic remedies on standard medication histories because they don’t consider them “medications.” Use specific prompts: “Any teas, powders, vitamins, weight-loss products, muscle-building products, or anything from a health food store?” — and review actual bottles when possible.
Pitfall — Attributing DILI to a long-standing chronic medicationThe default assumption should be that the most recently added drug is the culprit. A drug taken for 5+ years without LFT change is rarely the cause of acute injury — although there are notable exceptions (nitrofurantoin, methotrexate, amiodarone, methyldopa, statins rarely). Review the timeline carefully and challenge any attribution that conflicts with the typical latency profile.
Pearl — Use LiverTox before deciding causalityThe LiverTox database (livertox.nih.gov) provides drug-by-drug hepatotoxicity profiles with onset patterns, RUCAM scores, and case literature. A drug with a Likelihood Score A (well-established) and a published case series matching your patient’s pattern carries far stronger causality than a Likelihood Score E* (unlikely) drug. Document the LiverTox lookup in your assessment.
Pitfall — Empiric corticosteroids without evidence of immune mechanismStarting prednisone for “suspected DILI” without features of AIH, DRESS, or ICI hepatitis is unsupported and exposes the patient to infection and metabolic complications. Reserve steroids for: drug-induced AIH (positive autoantibodies + biopsy), DRESS, ICI hepatitis grade ≥2, and selected refractory cholestatic DILI in consultation with hepatology.
Pearl — NAC works in non-acetaminophen ALF tooThe ALFSG trial (NEJM 2009) demonstrated that IV NAC improved transplant-free survival in non-acetaminophen ALF with grade I–II encephalopathy. Do not reserve NAC for acetaminophen-only cases — start it in any ALF with early encephalopathy while etiology is being clarified. Side effects are limited to anaphylactoid reactions (slow infusion, pretreat with antihistamine).
Pitfall — Restarting the suspected drug because “the patient improved”Inadvertent or deliberate rechallenge has caused fatal massive hepatic necrosis. The fact that LFTs improved with dechallenge does NOT mean the drug is safe — it confirms causality. Document a permanent allergy/intolerance entry in the medical record and counsel the patient explicitly about lifelong avoidance.

Frequently Asked Questions

How long after starting a new medication should I worry about DILI?
Most idiosyncratic DILI presents within 5 to 90 days of starting a new medication, with peak incidence at 4 to 8 weeks. However, important exceptions exist: amiodarone DILI may develop after months to years, methotrexate-related fibrosis after years of cumulative dosing, and isoniazid hepatitis can occur up to 6 months into therapy. Acetaminophen toxicity follows acute overdose by 24 to 72 hours. Always review the full medication timeline including over-the-counter products and supplements added in the past 6 months.
Should I check baseline LFTs before starting a hepatotoxic medication?
Yes for high-risk drugs: isoniazid (baseline + monthly × 6 months), methotrexate (baseline + every 4–8 weeks, transition to FibroScan annually), amiodarone (baseline + every 6 months), terbinafine (baseline + 4–6 weeks), valproate (baseline + every 1–3 months), and antiepileptic combinations. For most other drugs including statins, routine baseline-only LFTs are reasonable; routine periodic monitoring of statin LFTs is no longer recommended. ICI patients require LFTs before each cycle.
What is the role of liver biopsy in DILI?
Liver biopsy is reserved for cases where the diagnosis is unclear, autoimmune hepatitis is suspected (to confirm AIH features and guide steroid therapy), severe ongoing injury despite drug withdrawal, or persistent cholestatic injury beyond 3 months (to exclude vanishing bile duct syndrome). Biopsy can identify eosinophilic infiltrates (suggestive of hypersensitivity), granulomas (allopurinol, sulfa drugs), zonal necrosis patterns, steatosis (amiodarone, methotrexate), or sinusoidal obstruction. It is not routinely required when the temporal pattern and exclusion workup support DILI.
Is N-acetylcysteine safe in pregnancy and breastfeeding?
Yes. NAC crosses the placenta and reaches the fetus, where it provides protective benefit in maternal acetaminophen overdose. The standard 21-hour IV Prescott protocol is recommended for any acetaminophen overdose during pregnancy regardless of trimester. NAC is also compatible with breastfeeding. Maternal acetaminophen overdose carries significant fetal risk, so timely NAC is essential.
When can I rechallenge a patient with a drug suspected of causing DILI?
Generally never for severe DILI (Hy’s Law positive, ALF, DRESS, immune-mediated). For mild DILI where the drug is essential and no alternative exists (e.g., antitubercular therapy, certain chemotherapy), structured reintroduction under specialist supervision with frequent LFT monitoring may be considered after discussion of risks. Inadvertent rechallenge has caused fatal massive hepatic necrosis and is contraindicated.
How do I distinguish DILI from autoimmune hepatitis?
Both can produce hepatocellular injury, positive autoantibodies, and elevated IgG. Features favoring AIH: female, IgG >1.5× ULN, ASMA or anti-LKM-1 strongly positive, classic interface hepatitis with plasma cell infiltrate on biopsy, rapid relapse after steroid taper. Features favoring drug-induced AIH: clear temporal relationship to drug exposure, complete resolution after drug withdrawal and steroid taper without relapse, biopsy without classic interface hepatitis. Drug-induced AIH responds to steroids but typically does not require lifelong immunosuppression.
What is the long-term prognosis after DILI?
Most patients recover completely within 6 months of drug withdrawal — approximately 75–90% normalize LFTs by 12 months. About 10–20% develop chronic DILI defined as persistent biochemical abnormality >6 months after withdrawal. Cholestatic DILI carries higher risk of chronic injury including vanishing bile duct syndrome (rare but progressive). Acute mortality is approximately 10% for Hy’s Law-positive cases and up to 50% for non-acetaminophen ALF. Patients who survive without transplant generally have full functional recovery.
↑
GUIDELINE REFERENCES

Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.

Leave a Reply

Your email address will not be published. Required fields are marked *